Cookies?
Library Header Image
LSE Research Online LSE Library Services

Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge

Handels, Ron L.H., Green, Colin, Gustavsson, Anders, Herring, William L., Winblad, Bengt, Wimo, Anders, Sköldunger, Anders, Karlsson, Andreas, Anderson, Robert, Belger, Mark, Brück, Chiara, Espinosa, Robert, Hlávka, Jakub P., Jutkowitz, Eric, Lin, Pei Jung, Mendez, Mauricio Lopez, Mar, Javier, Shewmaker, Peter, Spackman, Eldon, Tafazzoli, Ali, Tysinger, Bryan and Jönsson, Linus (2023) Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge. Alzheimer's and Dementia, 19 (5). 1800 - 1820. ISSN 1552-5260

[img] Text (Alzheimer s Dementia - 2022 - Handels - Cost‐effectiveness models for Alzheimer s disease and related dementias IPECAD (1)) - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (683kB)
Identification Number: 10.1002/alz.12811

Abstract

Introduction: The credibility of model-based economic evaluations of Alzheimer's disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer's Disease (IPECAD) Modeling Workshop Challenge.  Methods: Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were developed jointly by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop.  Results: A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in the control group ranged across 10 MCI models from 6.7 to 9.5 years and 3.4 to 5.6 years, respectively; and across 4 mild dementia models from 5.4 to 7.9 years (survival) and 1.5 to 4.2 years (mild dementia).  Discussion: The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible AD models.

Item Type: Article
Official URL: https://alz-journals.onlinelibrary.wiley.com/journ...
Additional Information: © 2022 The Authors
Divisions: LSE
Care Policy and Evaluation Centre
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited: 05 Sep 2022 14:54
Last Modified: 29 Nov 2024 01:29
URI: http://eprints.lse.ac.uk/id/eprint/116444

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics